The role of miR-3654 in dysregulating glucose and lipid metabolism in polycystic ovary syndrome through SLC2A1

Abstract Objectives Polycystic ovary syndrome (PCOS) is a prevalent endocrine and metabolic disorder. This study aimed to evaluate the diagnostic potential of microRNA-3654 (miR-3654) in PCOS and to elucidate its biological function in an in vitro model. Methods Serum expression levels of miR-3654 and solute carrier family 2 member 1 ( SLC2A1 ) were detected by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in 85 patients with PCOS and 85 control subjects. The correlation between miR-3654 levels and luteinizing hormone (LH) was assessed via Pearson correlation analysis. Then, the interaction between miR-3654 and SLC2A1 was verified by a dual-luciferase reporter assay. In addition, RT-qPCR, Western blot, and commercial kits were used to evaluate the effects of miR-3654 on glycolysis markers and key lipid metabolism factors mediated by SLC2A1 . Results Serum levels of miR-3654 were significantly upregulated in patients with PCOS (n=85, p<0.001), with a ROC curve AUC of 0.8127 (p<0.001). Its expression was positively correlated with LH (r=0.6839, p<0.0001) in PCOS patients. In testosterone-induced KGN (T-KGN) cells, miR-3654 inhibition significantly restored HK2 and LDHA expression (both p<0.001), enhanced lactate production (p<0.001), reduced pyruvate accumulation (p<0.001), and upregulated PPARγ , PGC-1α , and HMGCR (all p<0.001). SLC2A1 expression was significantly downregulated in both PCOS patients (p<0.001) and T-KGN cells (p<0.001). Crucially, the metabolic effects resulting from miR-3654 inhibition were reversed when SLC2A1 expression was concurrently suppressed (all p<0.05). Conclusions MiR-3654 held promise as a diagnostic biomarker for PCOS. Mechanistically, miR-3654 negatively targeted and regulated SLC2A1 , thereby disrupting glycolytic and lipid metabolic homeostasis in ovarian granulosa cells and contributing to the glycolipid metabolic disorders observed in PCOS.

Authors

Institutions

Publication Details

Journal
Turkish Journal of Biochemistry
Published
2026-11-16
DOI
https://doi.org/10.1515/tjb-2026-0037
Primary Topic
Ovarian function and disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The role of miR-3654 in dysregulating glucose and lipid metabolism in polycystic ovary syndrome through SLC2A1

Xiaoqing Zhu, Jing Bai, Lulu Wang
3 links
Turkish Journal of Biochemistry
Ovarian function and disorders
article

The role of miR-3654 in dysregulating glucose and lipid metabolism in polycystic ovary syndrome through SLC2A1

Xiaoqing Zhu, Jing Bai, Lulu Wang
article en

Abstract

Abstract Objectives Polycystic ovary syndrome (PCOS) is a prevalent endocrine and metabolic disorder. This study aimed to evaluate the diagnostic potential of microRNA-3654 (miR-3654) in PCOS and to elucidate its biological function in an in vitro model. Methods Serum expression levels of miR-3654 and solute carrier family 2 member 1 ( SLC2A1 ) were detected by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in 85 patients with PCOS and 85 control subjects. The correlation between miR-3654 levels and luteinizing hormone (LH) was assessed via Pearson correlation analysis. Then, the interaction between miR-3654 and SLC2A1 was verified by a dual-luciferase reporter assay. In addition, RT-qPCR, Western blot, and commercial kits were used to evaluate the effects of miR-3654 on glycolysis markers and key lipid metabolism factors mediated by SLC2A1 . Results Serum levels of miR-3654 were significantly upregulated in patients with PCOS (n=85, p<0.001), with a ROC curve AUC of 0.8127 (p<0.001). Its expression was positively correlated with LH (r=0.6839, p<0.0001) in PCOS patients. In testosterone-induced KGN (T-KGN) cells, miR-3654 inhibition significantly restored HK2 and LDHA expression (both p<0.001), enhanced lactate production (p<0.001), reduced pyruvate accumulation (p<0.001), and upregulated PPARγ , PGC-1α , and HMGCR (all p<0.001). SLC2A1 expression was significantly downregulated in both PCOS patients (p<0.001) and T-KGN cells (p<0.001). Crucially, the metabolic effects resulting from miR-3654 inhibition were reversed when SLC2A1 expression was concurrently suppressed (all p<0.05). Conclusions MiR-3654 held promise as a diagnostic biomarker for PCOS. Mechanistically, miR-3654 negatively targeted and regulated SLC2A1 , thereby disrupting glycolytic and lipid metabolic homeostasis in ovarian granulosa cells and contributing to the glycolipid metabolic disorders observed in PCOS.

Turkish Journal of Biochemistry
China Three Gorges University (CN), Yichang Central People's Hospital (CN)
Good health and well-being
Ovarian function and disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon